EVOLVE YOUR
STRATEGY with TALVEY® (talquetamab-tgvs)
TALVEY® is the first and only FDA-approved
GPRC5D-targeting agent1,2
Consider the importanceof different targets in RRMM
GPRC5D, G protein-coupled receptor class C group 5 member D; RRMM, relapsed or refractory multiple myeloma.
SEE THE VERSATILITY
of TALVEY®
For patients both naïve and exposed to T-cell redirection therapy1
SEE THE SUPPORT
TALVEY® offers a variety
of resources for you and
your patients
CD, cluster of differentiation; FDA, U.S. Food and Drug Administration; GPRC5D, G protein-coupled receptor class C group 5 member D; PI, proteasome inhibitor; RRMM, relapsed or refractory multiple myeloma.
CD, cluster of differentiation; FDA, U.S. Food and Drug Administration; GPRC5D, G protein-coupled receptor class C group 5 member D; PI, proteasome inhibitor; RRMM, relapsed or refractory multiple myeloma.
- TALVEY® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- U.S. FDA approves TALVEY® (talquetamab-tgvs), a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma. Janssen Biotech, Inc. Updated August 10, 2023. Accessed October 1, 2025. https://www.janssen.com/fda-approves-talveytmtalquetamab-tgvs-first-class-bispecific-therapy-treatment-patients-heavily